FDA Approves 6-in-1 Vaccine from Merck and Sanofi

FDA Approves 6-in-1 Vaccine from Merck and Sanofi

January 4, 2019 — The FDA has just approved a 6-in-1 shot that combines immunizations against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Hib disease.

Sanofi Pasteur and Merck & Co. developed the hexavalent (“six-in-one”) vaccine in a joint partnership. They are calling it Vaxelis.

The vaccine combines DTP antigens, which are manufactured by Sanofi, with Hib and HBV antigens manufactured by Merck.

Vaxelis is intended to be administered in 3 separate doses to infants and children who are at least 6 weeks old and under 5 years old.

The vaccine will not be offered until 2020 at the earliest in the U.S., according to Sanofi, which said it was working with Merck to “allow for a sustainable supply to meet anticipated US demand.”

Vaxelis was approved 3 years ago in Europe and it reached the market in 2016.

It is the latest effort from drug-makers to reduce the number of shots for children. The vaccine also cuts back on the number of vaccines that need to be stored and transported, which helps simplify the role of medical staff.

Source: Sanofi, Merck win FDA nod for 6-in-1 pediatric vaccine Vaxelis

Vaccine Side Effects & Injury Lawyers

Verified 100% Secure Site

If you or a loved one has been the victim of a vaccine side effect, you should contact a vaccine lawyer with experience in this type of complex litigation.

We have recently partnered with Schmidt & Clark, LLP; a Nationally recognized law firm who handles vaccine lawsuits in all 50 states.

The lawyers at the firm offer a Free Confidential Case Evaluation and may be able to obtain financial compensation for you or a loved one by filing a vaccine lawsuit or claim with The National Vaccine Injury Compensation Program. Contact Schmidt & Clark today by using the form below or by calling them directly at (866) 223-3784.

Previous Article
Next Article

Leave a Reply

Your email address will not be published. Required fields are marked *